

ARO ADMISSION SCREENING – IP&C HIGHLIGHTS

Note: Refer to Admission Screening for Antibiotic Resistant Organisms Operational Directive in WRHA IP&C Manual for complete protocol

ARO ADMISSION SCREENING		
CONTACT IP&C	C For any patients who have been admitted to hospital outside of Canada in last 6 months	
	PURPOSE	
REDUCE HAIS	Reduce risk of healthcare associated transmission of antibiotic resistant organisms (AROs)	
	DEFINITION	
ADMISSION	Any stay in hospital greater than (>) 24 hours, including any stay in Emergency > 24 continuous hours	
ADIVIISSION	SCREENING, ISOLATION PRECAUTIONS, TESTING	
	METHICILLIN RESISTANT STAPHYLOCOCCUS	CARBAPENEMASE- PRODUCING
	AUREUS (MRSA)	ENTEROBACTERIACEAE (CPE)
SCREENING CRITERIA	Confirm on <i>each</i> admission as well as at Pre- Operative Assessment Clinic (PAC) visit, if	Confirm on <i>each</i> admission as well as at Pre- Operative Assessment Clinic (PAC) visit, if patient
CRITERIA	 patient meets any screening criteria listed: Admitted to or directly transferred from a health care facility, including PCHs, within or outside Canada within previous 6 months, where admitted for more than 24 hours Inter-facility Transfer/Referral Form indicates admission screening required Identified as MRSA POS in flagging system Identified as MRSA SUS in flagging system Identified as MRSA Contact Once known as MRSA POS and whose positive status is currently unknown Starting dialysis or new to dialysis unit Living in a correction setting or communal living setting (e.g., group home) NOTE: Do NOT collect screening cultures for patients admitted to Mental Health units. If patient then transferred to another area of facility, screen if above criteria met. 	 Meets screening criteria listed: Admitted to or directly transferred from any facility known to have endemic transmission (as discussed with IP&C) in previous 6 months. Consider facilities within or outside Canada, including current facility Identified as CPE SUS in flagging system Identified as a CPE contact
PATIENTS REFUSING	If MRSA screening refused , explain procedure/ rationale for screening again. If still refused ,	If CPE screening refused , explain procedure/ rationale for screening again. If still refused ,
SCREENING	where possible, place patient on <u>Contact</u> Precautions for duration of stay; notify IP&C	isolate patient and place on Contact Precautions for duration of stay; notify IP&C
SCREENING SPECIMENS	Specimen collection sites include: • Anterior nares (both nares, one swab) • Open wounds/lesions/incisions/invasive device insertion sites (e.g., central lines). Do not collect from closed/healed wounds/lesions/incisions • Send specimen(s) to Microbiology Laboratory	CONTACT IP&C/delegate prior to specimen collection Specimen collection from rectal/ostomy site. NOTE: Peri-rectal swabs, instead of rectal swabs may be submitted for neonatal, pediatric, adolescent & immune-compromised patients.
CONTACT PRECAUTIONS	 Implement Contact Precautions and notify IP&C when patients meet ANY following criteria: Identified as MRSA POS in flagging system Admitted to or directly transferred from an acute care hospital (including ER) outside Canada within previous 6 months, pending screening results Patients who have received hemodialysis treatment outside Manitoba where negative screening cultures obtained within 7 days prior to arrival at WRHA facility are not available, pending screening results Refusal of MRSA screening despite explanation of procedure/rationale having been repeated NOTE: not all patients who have tested positive for MRSA are identified in EPR. If documentation from other sources indicates patient has MRSA, notify ICP.	 Implement Contact Precautions and notify IP&C when patients meet ANY following criteria: Identified CPE POS in flagging system Identified as CPE SUS in flagging system Admitted to or directly transferred from an acute care hospital (including ER) outside